Loading company…
WuXi XDC provides discovery, development and manufacturing services for antibody-drug conjugates and other bio-conjugates.
Founded in 2018 and based in Wuxi, China, WuXi XDC provides single-source discovery, development, and manufacturing services for antibody-drug conjugates and other bio-conjugates. Its services include bio-conjugation discovery and process development, as well as GMP mAb intermediate and conjugation manufacturing. The company has served more than 300 clients, including Genentech and Merck. It raised HKD 2.346 billion in pre-IPO funding in November 2023 and listed on the Hong Kong Stock Exchange that month.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in